High-sensitivity c-reactive protein and coronary heart disease in a general population of Japanese: The Hisayama study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 7, 2008, Pages 1385-1391

  Arima, Hisatomi ^a   Kubo, Michiaki ^a   Yonemoto, Koji ^a   Doi, Yasufumi ^a   Ninomiya, Toshiharu ^a   Tanizaki, Yumihiro ^a   Hata, Jun ^a   Matsumura, Kiyoshi ^a   Iida, Mitsuo ^a   Kiyohara, Yutaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

C reactive protein; Coronary heart disease; General population; Inflammation; Prospective cohort study

Indexed keywords

C REACTIVE PROTEIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; CARDIOVASCULAR RISK; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SUDDEN DEATH; AGED; ASIAN; BLOOD; CORONARY ARTERY DISEASE; ETHNOLOGY; HEALTH SURVEY; INFLAMMATION; JAPAN; METABOLISM; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; RISK; RISK ASSESSMENT; STATISTICS; TIME; UPREGULATION;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFLAMMATION; JAPAN; MALE; MIDDLE AGED; ODDS RATIO; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 46249105275     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.157164     Document Type: Article

References (33)

1. World Health Organization. The Atlas of Heart Disease and Stroke. Geneva: World Health Organization; 2004.
2. World Health Organization. Preventing Chronic Disease: A Vital Investment. Geneva: World Health Organization; 2005.
3. Rubo M, Riyohara Y, Rato I, Tanizaki Y, Arima H, Tanaka R, Nakamura H, Okubo R, lida M. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke. 2003;34:2349-2354.
4. Berliner JA, Navab M, Fogelman. AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995;91:2488-2496.
5. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
6. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu RR. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J. 2002;144:233-238.
7. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison, of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347: 1557-1565.
8. Luc G, Bard JM, Juhan-Vague I, Ferneres J, Evans A, Amouyel P, Arveiler D, Fruchart JC, Ducimetiere P. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vase Biol. 2003;23:1255-1261.
9. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599-2610.
10. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein, and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
11. Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham. SA, Wareham NJ, Peters RJ, Jukema JW, Day NE, Rastelein JJ, Rhaw RT. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population, study 1993-2003. Atherosclerosis. 2006;187:415-422.
12. Sattar N, Murray HM, McConnachie A, Blauw GJ, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Ramper AM, Macfarlane PW, Murphy MB, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, Shepherd J. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk. (PROSPER). Circulation. 2007;115:981-989.
13. Wakugawa Y, Riyohara Y, Tanizaki Y, Rubo M, Ninomiya T, Hata J, Doi Y, Okubo R, Oishi Y, Shikata R, Yonemoto R, Maebuchi D, Ibayashi S, lida M. C-reactive protein and risk, of first-ever ischemic and hemorrhagic stroke in a general Japanese population: the Hisayama Study. Stroke. 2006;37:27-32.
14. Arima H, Tanizaki Y, Riyohara Y, Tsuchihashi T, Rato I, Rubo M, Tanaka R, Ohkubo R, Nakamura H, Abe I, Fujishima M, lida M. Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: the Hisayama Study. Arch Intern. Med. 2003;163:361-366.
15. Arima H, Riyohara Y, Rato I, Tanizaki Y, Rubo M, Iwamoto H, Tanaka R, Abe I, Fujishima M. Alcohol reduces insulin-hypertension relationship in a general population: the Hisayama study. J Clin Epidemiol. 2002;55:863-869.
16. World Health Organization. ICD-10: International Statistical. Classification of Diseases and Related Health Problems: Tenth Revision - II Edition. Geneva: World Health Organization; 2004.
17. Friedewald W, Levy R, Fredrickson D. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA. 2001;285:2486-2497.
19. World Health Organisation/International Association for the Study of Obesity/International Obesity Task Force. The Asia-Pacific Perspective: Redefining Obesity and its Treatment. Available at: http://www.diabetes. com.au/pdf/obesityj-port.pdf.
20. Sakkinen P, Abbott RD, Curb JD, Rodriguez BL Yano R, Tracy RP. C-reactive protein and myocardial infarction. J Clin Epidemiol. 2002;55:445-451.
21. Albert MA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United. States (from the Women's Health Study). Am J Cardiol. 2004;93:1238-1242.
22. Matthews RA, Sowers MF, Derby CA, Stein E, Miracle-McMahill H, Crawford SL, Pasternak RC. Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN). Am Heart J. 2005;149:1066-1073.
23. Ishikawa J, Tarn ura Y, Hoshide S, Eguchi R, Ishikawa S, Shimada R, Kario K. Low-grade inflammation is a risk, factor for clinical stroke events in addition to silent cerebral infarcts in Japanese older hypertensives: the Jichi Medical School ABPM Study, wave 1. Stroke. 2007; 38:911-917.
24. Matsushita K, Yatsuya H, Tamakoshi K, Yang PO, Otsuka K, Wada K, Mitsuhashi H, Hotta Y, Rondo T, Murohara T, Toyoshima H. Highsensitivity C-reactive protein is quite low in Japanese men at high coronary risk. Circ J. 2007;71:820-825.
25. MacGregor AJ, Gallimore JK, Spector TD, Pepys MB. Genetic effects on baseline values of C-reactive protein and serum, amyloid a protein: a comparison of monozygotic and dizygotic twins. Clin Chem. 2004;50:130-134.
26. Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem. 2003;49:1258-1271.
27. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28.
28. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/1: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005;45:1644-1648.
29. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, Rifai N, Califf RM, Braunwald E. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006;114:281-288.
30. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert R, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health, practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the Am Heart Association. Circulation. 2003;107:499-511.
31. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145:21-29.
32. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk, in women: the Reynolds Risk. Score. JAMA. 2007;297: 611-619.
33. Pearson TA, Bazzarre TL, Daniels SR, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Hong Y, Mensah GA, Sallis JF Jr, Smith S Jr, Stone NJ, Taubert KA. Am Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the Am Heart Association Expert Panel on Population and Prevention Science. Circulation. 2003; 107:645-651.